iosBio | 1,200 followers on LinkedIn. iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. | iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraPro™ platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail. iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe.